Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe

被引：20
作者：
Gyawali C.P. [1 ]
机构：
[1] Division of Gastroenterology, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8124, St. Louis, 63110, MO
来源：
Current Gastroenterology Reports | 2017年 / 19卷 / 9期
关键词：
Ambulatory reflux monitoring; Endoscopy; Esophageal manometry; Gastroesophageal reflux disease; Proton pump inhibitors: heartburn;
D O I：
10.1007/s11894-017-0586-5
中图分类号：
学科分类号：
摘要：
Purpose of Review: Proton pump inhibitor (PPI) use in gastroesophageal reflux disease (GERD) has been redefined, in light of recent advances highlighting GERD phenotypes that respond to PPIs, and fresh revelations of potential risks of long-term PPI therapy. Recent Findings: Erosive esophagitis predicts excellent response to PPI therapy, but non-erosive reflux disease (NERD) with abnormal reflux parameters on ambulatory reflux monitoring also demonstrates a similar response. In contrast, response is suboptimal in the absence of abnormal reflux parameters. In this setting, if an alternate appropriate indication for PPI therapy does not coexist, risks may outweigh benefits of PPI therapy. Adverse events from long-term PPI therapy continue to be reported, most based on association rather than cause-and-effect. Summary: Appropriate indications need to be established before embarking on long-term PPI therapy. Future research will define true risks of long-term PPI therapy, and develop alternate management options for acid peptic diseases. © 2017, Springer Science+Business Media, LLC.
引用
收藏
相关论文
共 100 条
  • [11] Shaheen N.J., Weinberg D.S., Denberg T.D., Et al., Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians, Ann Intern Med, 157, pp. 808-816, (2012)
  • [12] Katz P.O., Gerson L.B., Vela M.F., Guidelines for the diagnosis and management of gastroesophageal reflux disease, Am J Gastroenterol, 108, pp. 300-308, (2013)
  • [13] CD002095, (2013)
  • [14] Khan M., Santana J., Donnellan C., Et al., Medical treatments in the short term management of reflux oesophagitis, Cochrane Database Syst Rev, (2007)
  • [15] Weijenborg P.W., Cremonini F., Smout A.J., Et al., PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis, Neurogastroenterol Motil, 24, pp. 740-747, (2012)
  • [16] Aziz Q., Fass R., Gyawali C.P., Et al., Functional esophageal disorders, Gastroenterology, 150, pp. 1368-1379, (2016)
  • [17] Weijenborg P.W., Smout A.J., Bredenoord A.J., Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn, Neurogastroenterol Motil, 28, pp. 1649-1654, (2016)
  • [18] Savarino E., Zentilin P., Frazzoni M., Et al., Characteristics of gastro-esophageal reflux episodes in Barrett’s esophagus, erosive esophagitis and healthy volunteers, Neurogastroenterol Motil, 22, pp. 1061-1280, (2010)
  • [19] Roman S., Et al., Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group, (2017)
  • [20] Scarpignato C., Gatta L., Zullo A., Et al., Effective and safe proton pump inhibitor therapy in acid-related diseases—A position paper addressing benefits and potential harms of acid suppression, BMC Med, 14, (2016)
12345678910